Dear Shareholders,

Psyence BioMed CEO Jody Aufrichtig was recently featured in POLITICO’s Prescription Pulse, discussing the rapidly growing interest in ibogaine and the critical importance of building the manufacturing, regulatory, and supply chain infrastructure needed to support its future development as a therapeutic treatment.

As policymakers, researchers, healthcare institutions, and veterans’ advocates increasingly explore ibogaine’s potential, Psyence BioMed continues to position itself at the forefront of this emerging sector.

Through our strategic investment in PsyLabs, we have established pharmaceutical-grade manufacturing capabilities, ethical sourcing partnerships in Africa, and the expertise required to support clinical research and future commercialization efforts.

The article also highlighted a principle that remains central to our long-term vision: ensuring that the communities and original custodians of the iboga plant are meaningful participants in the value created by the global ibogaine industry.

We believe the future of ibogaine must be built on a foundation of scientific rigor, sustainable cultivation, responsible regulation, and equitable partnerships. Building on this momentum, members of our leadership team will travel to the United States next month to meet with researchers, institutions, industry leaders, veterans’ organizations, and government stakeholders involved in advancing psychedelic medicine. These engagements will focus on the scientific, regulatory, and manufacturing requirements necessary to support pharmaceutical-grade ibogaine research and future therapeutic applications.

The growing attention being given to ibogaine at both the state and federal levels represents an important milestone for the field. We remain committed to helping build the infrastructure, partnerships, and supply capabilities needed to support its responsible development worldwide.

As Jody stated in the interview:

“Our goal is to lay the foundations for the use of ibogaine worldwide.”

For those interested in learning more, the article appeared in POLITICO’s Prescription Pulse on May 19, 2026.